Flavivirus domain iii vaccine
AssigneeUniversity of Rochester
InventorsJacob J. Schlesinger, Xia Jin, Robert C. Rose, Olivia K.T. Block, W.W. Shanaka I. Rodrigo
Life of this patent
Estimating the term…
Abstract
The disclosure provides a tetravalent Dengue virus vaccine, and methods of inducing a immune response against a Flavivirus such as Dengue virus 1-4 using the vaccine. The disclosure also provides methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dill polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses.
Claims36
A tetravalent Dengue virus vaccine comprising:
- a Dengue domain III polypeptide for each of DEN1 to DEN4, wherein the vaccine induces a neutralizing antibody response against each of DEN1 to DEN4 that exceeds PRNT50 value of 200.
7-8. (canceled)
10-12. (canceled)
(canceled)
(canceled)
A multivalent vaccine comprising:
- an effective amount of a Dengue domain III polypeptide for each of DEN1 to DEN4,
- an effective amount of a Yellow Fever domain III polypeptide, and
- a pharmaceutically acceptable carrier.
28-31. (canceled)
A method of making a vaccine comprising:
- introducing into a host cell a transgene that encodes a recombinant protein comprising a secretion signal in-frame with a Flavivirus domain III (dIII) polypeptide;
- growing the host cell under conditions effective to express the recombinant protein in soluble form;
- recovering the recombinant protein in the absence of one or more refolding steps;
- cleaving the secretion signal from the recovered protein to obtain a dIII polypeptide;
- and
- combining, with a pharmaceutically acceptable vehicle, dIII polypeptide specific for multiple Flaviviruses in amounts effective to induce a neutralizing immune response against each of the Flaviviruses that exceeds PRNT50 of 150.
(canceled)
(canceled)
42-50. (canceled)
Dependencies are inferred from the claim text.